Apeloa Pharmaceutical, a leading international Generic Active Pharmaceutical Ingredients (API) supplier, has been making waves in the pharmaceutical industry with its commitment to innovation, diversification, and growth. With a market cap of CNY 17.79 billion and an enterprise value of CNY 14.87 billion, the company has demonstrated strong financial performance and a promising future.



Apeloa Pharmaceutical's diverse product portfolio includes cardio-cerebrovascular, anti-infection, anti-tumor, anti-viral, and special drugs. This diversification helps the company cater to various market needs and reduces reliance on a single product or therapeutic area. In 2024, Apeloa Pharmaceutical's subsidiary, Kangyu Pharmaceutical, received approval for Simeglutide injections for weight management and type 2 diabetes in adults, expanding its product portfolio in the diabetes treatment market.

The company's strong R&D pipeline, with several clinical trials underway, indicates its commitment to exploring new opportunities. For example, Apeloa Pharmaceutical is developing Fluvastatin Sodium Sustained Release Tablets (CTR20241670) to evaluate its bioequivalence in healthy subjects. Additionally, the company is working on Oseltamivir Phosphate Dry Powder Inhalation (DPI) (CTR20234297) and Amoxicillin and Clavulanic Acid Tablets (CTR20233726) to assess their bioequivalence in healthy subjects.



Apeloa Pharmaceutical's strategic partnerships, such as the one with Biocre Biotechnology, enable the company to leverage cutting-edge technologies and expand its product offerings. This collaboration allows Apeloa Pharmaceutical to develop and produce high-value biosynthetic products, including functional proteins, peptides, APIs, and medical cosmetics.

In conclusion, Apeloa Pharmaceutical's diverse product portfolio, strong R&D pipeline, investment in technology and innovation, and strategic partnerships contribute significantly to its long-term prospects. The company's commitment to innovation, diversification, and growth, along with its strong financial performance, positions it as a promising player in the global API market. As the company continues to expand its product offerings and explore new opportunities, investors can expect Apeloa Pharmaceutical to maintain its competitive edge and deliver strong returns.